We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Two Checkpoint Inhibitors Were Better Than One for NSCLC Patients, Trial Results Show
Two Checkpoint Inhibitors Were Better Than One for NSCLC Patients, Trial Results Show
Adding two immune checkpoint inhibitors to platinum-based chemotherapy extended progression-free survival and reduced the risk of death in patients with metastatic small-cell lung cancer, relative to a single blocker/chemo combination or chemotherapy alone.